Document Detail


Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.
MedLine Citation:
PMID:  23154633     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Many neurodegenerative diseases such as Alzheimer disease and Parkinson disease show similar characteristics. They typically show deposits of protein aggregates, the formation of which is considered important in their pathogenesis. Recently, aggregation-prone proteins have been shown to spread between cells and so may contribute to the pathogenesis of diseases like prion disease. Such a pathogenesis pathway is possibly common to many neurodegenerative diseases. If confirmed, it could allow the development of therapeutic interventions against many such diseases. In Parkinson disease, α-synuclein, a major component of cytosolic protein inclusions named Lewy body, has been shown to be released and taken up by cells, which may facilitate its progressive pathological spreading between cells. Accordingly, inhibition of spreading by targeting extracellular α-synuclein may represent a new therapy against Parkinson disease. Research into the intercellular spreading of extracellular protein aggregations of α-synuclein and its clearance pathway are reviewed here with a focus on the proteolytic clearance pathway as a therapeutic target for the treatment of Parkinson disease. Considering the similar characteristics of aggregation-prone proteins, these clearance systems might allow treatment of other neurodegenerative diseases beyond Parkinson disease.
Authors:
Sang Myun Park; Kwang Soo Kim
Related Documents :
16030803 - Pneumonia of pigs: a review.
1246203 - Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases an...
17604483 - Creutzfeldt-jakob disease presenting with confusion and visual disturbance.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-15
Journal Detail:
Title:  Prion     Volume:  7     ISSN:  1933-690X     ISO Abbreviation:  Prion     Publication Date:    2013 Mar-Apr
Date Detail:
Created Date:  2013-03-08     Completed Date:  2013-12-30     Revised Date:  2014-03-07    
Medline Journal Info:
Nlm Unique ID:  101472305     Medline TA:  Prion     Country:  United States    
Other Details:
Languages:  eng     Pagination:  121-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Delivery Systems
Extracellular Space / metabolism
Humans
Parkinson Disease / drug therapy*,  metabolism*
Prions / metabolism
Proteolysis
alpha-Synuclein / metabolism*
Chemical
Reg. No./Substance:
0/Prions; 0/alpha-Synuclein
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The prion protein family: Looking outside the central nervous system.
Next Document:  Cis phosphorylated tau as the earliest detectable pathogenic conformation in Alzheimer disease, offe...